Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

07.

- Cash flow statements

In 2008, ExonHit's net use of cash due to operating activities was EUR 9.6 million compared to EUR 4.9 million in 2007. This difference is mainly due to the increased operating losses and to the increased Research Tax Credit line.

The equipment necessary to strengthen our service laboratory and prepare it for GLP mainly explains the capital expenditure level of EUR 1.2 million in 2008, compared to EUR 1.1 million in 2007.

Due to unfavorable market conditions, financial operations generated EUR 0.2 million in 2008, to be compared with the generation of EUR 13.3 million in 2007.

Product Update

- Diagnostics

EHT Dx21, our internally developed blood diagnostic test for Alzheimer's disease (AD), is undergoing clinical validation. The clinical study EHT AD/002 initiated early in 2008 to recruit blood samples for patients suffering from AD, other dementias and controls achieved its first goal with the recruitment of 311 samples in Q3 2008. The second part of the study was initiated in January 2009 with the recruitment of 250 additional samples making the total number of samples included in the validation the largest for an array based AD blood diagnostic test.

Assuming successful clinical validation, ExonHit Therapeutics plans to launch EHT Dx21 as a Research Use Only product in the clinical trial market in Q4 2009, and in the clinical diagnostic market in a second step through a partnering model.

In February 2009, bioMerieux and ExonHit Therapeutics agreed on new research and development plans as part of their existing collaboration to develop blood-based cancer detection biomarkers. Both companies are jointly pursuing their programs on colorectal and prostate cancers (respectively EHT Dx12 and EHT Dx13) using ExonHit's next generation of human genome-wide SpliceArray(tm) biochips for biomarker disco
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
(Date:7/23/2014)... , July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: ... that it is filing for two medical marijuana dispensary locations ... are in addition to the Clark County, Nevada ... special use permit, as previously announced.  GrowBLOX Sciences, ... be submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
Breaking Biology Technology:BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5
... in Physical ... Quality of Life, SAN FRANCISCO, Oct. 27 ... injections of golimumab (CNTO 148),50 mg and 100 mg, ... skin symptoms of active psoriatic arthritis,through six months with ...
... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced ... that repeat administration with TRU-015 continues to ... arthritis,(RA) signs and symptoms based on American ... positive results following preliminary,analyses from a Phase ...
... MuriGen Therapeutics,today announced that its collaboration with ... drugs that target arthritis and other inflammatory diseases,has ... in February 2006 by MuriGen,Therapeutics and Zenyth Therapeutics ... therapeutic antibodies that inhibit the activity of the,cytokine ...
Cached Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 2WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 3
(Date:7/23/2014)... world by 2050, according to one of the scenarios ... may be advantageous to the physiology and the biochemical ... plants such as Stylosanthes capitata Vogel , a ... as Brazil., The conclusion is from a study carried ... the Ribeiro Preto Faculty of Philosophy, Sciences and Languages ...
(Date:7/23/2014)... SUP05 will play an increasingly important role in carbon ... minimum zones expand, according to research published this week ... Sciences . , University of British Columbia researchers plumbed ... Inlet, to chart how microbial community metabolism changes as ... very detailed picture of how SUP05 a bacterial ...
(Date:7/23/2014)... As of 2015, Springer will publish the International ... official journal of the Taiwan Fuzzy Systems Association (TFSA). ... global visibility in the area of fuzzy research., The ... to presenting high-quality papers that deal with the theory, ... gray systems and extension theory systems ranging from hardware ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Scientists are reporting the first-ever data to show that ... function of heart cells, and that loss of the protein ... Published Feb. 26 in the Journal of Biological ... online Feb. 19, the research was led by scientists at ...
... on Antarctica,s rich marine life are presented this week ... (AAAS). Marine Biologist Huw Griffiths from British Antarctic Survey ... the distribution and abundance of Antarctica,s vast marine biodiversity ... Griffiths presents results from the census which began ...
... BETHESDA, Md. (Feb. 16, 2010) A few minor ... endurance, according to a new study from Physiological Genomics ... more likely to have variations of the NRF2 gene than ... have the genetic variations compared to sprinters, although the difference ...
Cached Biology News:Scientists identify critical enzyme in healthy heart function 2Understanding global climate change through new breakthroughs in polar research 2Study finds variations in 1 gene may be associated with endurance running 2
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... [14C] Methylated Protein Molecular Weight Markers, ... proteins enable molecular weight determination of the ... allows visual monitoring of band migration in ... activity of the [14C] version without Rainbow-labeling ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
Biology Products: